VTE is a relatively common event, with a lifetime prevalence of approximately 1 in 20 people. Decisions about who to treat, with which drug, at what dose and for what duration can be complex. NPS Medicinewise have recently provided excellent guidance. Salient messages include:

  • Rivaroxaban or apixaban are the preferred treatments for most adults with acute VTE
  • Anticoagulation is required for people with proximal DVT or pulmonary embolism, and should continue for at least three months. For distal DVT may not necessarily require anticoagulation, but if implemented treatment may be used for 6-12 weeks
  • Aspirin is not recommended for extended treatment of venous thromboembolism
  • Pregnant women should not be treated with oral anticoagulation

For more details, read the full guidance here